Work

Agonistic CD40 antibody induces immune-mediated liver damage and modulates tumor-induced myeloid suppressive cells

Year: 2014

Type: article

Abstract: Meeting abstracts Immune stimulatory monoclonal antibodies are currently evaluated as anti/cancer agents in clinical trials. While overall toxicity seems to be moderate, liver toxicities have been reported and are not completely understood. Based on the observation that CD11b+Gr-1+ MDSC accumulate

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-p174

Authors: Jose Medina-Echeverz, Chi Ma, Austin Duffy, David E Kleiner, Tim F Greten

Institutions: National Cancer Institute, National Institutes of Health

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490